The North America PARP Inhibitor Biomarkers Market would witness market growth of 7.8% CAGR during the forecast period (2024-2031).
The US market dominated the North America PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $479.7 Million by 2031. The Canada market is experiencing a CAGR of 10.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.3% during (2024 - 2031).
The market refers to the sector within the healthcare industry focused on developing, commercializing, and utilizing biomarker testing technologies and services specifically related to PARP (poly (ADP-ribose) polymerase) inhibitors.
Moreover, these are a class of anticancer drugs that target enzymes involved in DNA repair processes, particularly in cancer cells with deficiencies in other DNA repair pathways, such as BRCA1 and BRCA2 mutations.
Higher healthcare expenditure may result in increased funding for healthcare infrastructure, including diagnostic laboratories and testing facilities in Canada. This can lead to improved access to biomarker testing services, including it, for patients across Canada. Increased availability of biomarker testing can facilitate earlier detection of biomarker-defined patient populations eligible for this therapy, thereby driving market growth.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $479.7 Million by 2031. The Canada market is experiencing a CAGR of 10.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.3% during (2024 - 2031).
The market refers to the sector within the healthcare industry focused on developing, commercializing, and utilizing biomarker testing technologies and services specifically related to PARP (poly (ADP-ribose) polymerase) inhibitors.
Moreover, these are a class of anticancer drugs that target enzymes involved in DNA repair processes, particularly in cancer cells with deficiencies in other DNA repair pathways, such as BRCA1 and BRCA2 mutations.
Higher healthcare expenditure may result in increased funding for healthcare infrastructure, including diagnostic laboratories and testing facilities in Canada. This can lead to improved access to biomarker testing services, including it, for patients across Canada. Increased availability of biomarker testing can facilitate earlier detection of biomarker-defined patient populations eligible for this therapy, thereby driving market growth.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Product- Kits
- Assays
- Breast Cancer
- Ovarian Cancer
- Others
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America PARP Inhibitor Biomarkers Market by Product
Chapter 5. North America PARP Inhibitor Biomarkers Market by Application
Chapter 6. North America PARP Inhibitor Biomarkers Market by Services
Chapter 7. North America PARP Inhibitor Biomarkers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
